In medullary thyroid cancer (MTC) with rearranged during transfection (RET) mutations, resistance to RET inhibitors may arise from secondary RET alterations and activation of bypass signaling pathways[8]. This evidence concerns the gene RET and medullary thyroid gland carcinoma.